NVS

Novartis

--(--)

Market Open: --

--(--)

Post-Market: --

Signals Analysis

Buy signal 2

Sell signal 1

Revenue Beats Expectation

Bullish Abandoned Baby

EPS Below Expectations

Key Stats

--DAY`S RANGE--

--52 WK RANGE--

Open

Prev.Close

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

Low

52 Week High

52 Week Low

About NVS

Novartis Ag

A Swiss leading global medicines company that develops branded and generic pharmaceuticals, consmer health products, vaccines and diagnostics

Industry

Pharmaceutical

Established Date

02/29/1996

Listing Date

05/12/2000

Exchange

New York Stock Exchange

Full-time Employees

75883

Fiscal Year Ends

12-31

Website

www.novartis.com

Security Type

Depository Receipts (Ordinary Shares)

Office address

Lichtstrasse 35, 4056 Basel, Switzerland

Business

Research, develop, manufacture and sell patented medicines in the fields of cancer and blood diseases

Introduction

Novartis AG was established in Switzerland on February 29, 1996. The Company is an innovative drug company engaged in the research, development, manufacturing, distribution, marketing and sales of various innovative drugs. The company's mission is to use its scientific expertise to find new ways to treat and cure diseases and reimagine medicine to improve and prolong people's lives. The company's business is divided into five organizational divisions: biomedical research, development, operations and two commercial divisions (US and International). Global functions support the work of these organizational units. The company focuses on four core therapeutic areas with strong growth potential and a large number of unmet patient needs — cardiovascular, renal and metabolism; immunology; neuroscience; and oncology.

Company Financials

EPS

NVS has released its 2024 Q4 earnings. EPS was reported at 1.98, versus the expected 1.78, beating expectations. The chart below visualizes how NVS has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

NVS has released its 2024 Q4 earnings report, with revenue of 13.56B, reflecting a YoY change of 15.13%, and net profit of 2.82B, showing a YoY change of -66.75%. The Sankey diagram below clearly presents NVS’s revenue sources and cost distribution.